Putting metabolic side effects into perspective: Risks versus benefits of atypical antipsychotics

Herbert Y. Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

The lengthy list of the side effects and morbidity associated with the atypical antipsychotics might make a patient with psychosis and his or her caregivers so concerned about the use of any of these medications, particularly those associated with a higher risk of diabetes, weight gain, or increased lipid levels, that they would prefer to avoid all of them. However, schizophrenia is associated with a relatively high risk for several diseases, including diabetes, that is independent of the risks that are linked to atypical antipsychotic use. Therefore, the clinician who might think, "Why use atypicals if using the typical drugs will escape the problems of monitoring and all the associated effects of diabetes and hyperglycemia?" needs to know that these problems cannot be avoided simply by choosing typical antipsychotics. Clinicians, patients, and concerned family members must balance the significant benefits of atypical antipsychotic treatment - improved cognition, reduced suicidality, and less depression - against the risks of metabolic disturbances and select a course of treatment that includes a realistic monitoring program.

Original languageEnglish (US)
Pages (from-to)35-39
Number of pages5
JournalJournal of Clinical Psychiatry
Volume62
Issue numberSUPPL. 27
StatePublished - Dec 1 2001

Fingerprint

Antipsychotic Agents
Hyperglycemia
Psychotic Disorders
Cognition
Caregivers
Weight Gain
Schizophrenia
Depression
Morbidity
Lipids
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

@article{84fba12e739846fa86b7b738111515c3,
title = "Putting metabolic side effects into perspective: Risks versus benefits of atypical antipsychotics",
abstract = "The lengthy list of the side effects and morbidity associated with the atypical antipsychotics might make a patient with psychosis and his or her caregivers so concerned about the use of any of these medications, particularly those associated with a higher risk of diabetes, weight gain, or increased lipid levels, that they would prefer to avoid all of them. However, schizophrenia is associated with a relatively high risk for several diseases, including diabetes, that is independent of the risks that are linked to atypical antipsychotic use. Therefore, the clinician who might think, {"}Why use atypicals if using the typical drugs will escape the problems of monitoring and all the associated effects of diabetes and hyperglycemia?{"} needs to know that these problems cannot be avoided simply by choosing typical antipsychotics. Clinicians, patients, and concerned family members must balance the significant benefits of atypical antipsychotic treatment - improved cognition, reduced suicidality, and less depression - against the risks of metabolic disturbances and select a course of treatment that includes a realistic monitoring program.",
author = "Meltzer, {Herbert Y.}",
year = "2001",
month = "12",
day = "1",
language = "English (US)",
volume = "62",
pages = "35--39",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 27",

}

Putting metabolic side effects into perspective : Risks versus benefits of atypical antipsychotics. / Meltzer, Herbert Y.

In: Journal of Clinical Psychiatry, Vol. 62, No. SUPPL. 27, 01.12.2001, p. 35-39.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Putting metabolic side effects into perspective

T2 - Risks versus benefits of atypical antipsychotics

AU - Meltzer, Herbert Y.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - The lengthy list of the side effects and morbidity associated with the atypical antipsychotics might make a patient with psychosis and his or her caregivers so concerned about the use of any of these medications, particularly those associated with a higher risk of diabetes, weight gain, or increased lipid levels, that they would prefer to avoid all of them. However, schizophrenia is associated with a relatively high risk for several diseases, including diabetes, that is independent of the risks that are linked to atypical antipsychotic use. Therefore, the clinician who might think, "Why use atypicals if using the typical drugs will escape the problems of monitoring and all the associated effects of diabetes and hyperglycemia?" needs to know that these problems cannot be avoided simply by choosing typical antipsychotics. Clinicians, patients, and concerned family members must balance the significant benefits of atypical antipsychotic treatment - improved cognition, reduced suicidality, and less depression - against the risks of metabolic disturbances and select a course of treatment that includes a realistic monitoring program.

AB - The lengthy list of the side effects and morbidity associated with the atypical antipsychotics might make a patient with psychosis and his or her caregivers so concerned about the use of any of these medications, particularly those associated with a higher risk of diabetes, weight gain, or increased lipid levels, that they would prefer to avoid all of them. However, schizophrenia is associated with a relatively high risk for several diseases, including diabetes, that is independent of the risks that are linked to atypical antipsychotic use. Therefore, the clinician who might think, "Why use atypicals if using the typical drugs will escape the problems of monitoring and all the associated effects of diabetes and hyperglycemia?" needs to know that these problems cannot be avoided simply by choosing typical antipsychotics. Clinicians, patients, and concerned family members must balance the significant benefits of atypical antipsychotic treatment - improved cognition, reduced suicidality, and less depression - against the risks of metabolic disturbances and select a course of treatment that includes a realistic monitoring program.

UR - http://www.scopus.com/inward/record.url?scp=0035685064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035685064&partnerID=8YFLogxK

M3 - Review article

C2 - 11806488

AN - SCOPUS:0035685064

VL - 62

SP - 35

EP - 39

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 27

ER -